U.S. Markets closed
  • S&P Futures

    3,852.00
    +3.75 (+0.10%)
     
  • Dow Futures

    31,041.00
    +28.00 (+0.09%)
     
  • Nasdaq Futures

    11,902.00
    +21.75 (+0.18%)
     
  • Russell 2000 Futures

    1,731.60
    +3.00 (+0.17%)
     
  • Crude Oil

    98.20
    -0.33 (-0.33%)
     
  • Gold

    1,741.40
    +4.90 (+0.28%)
     
  • Silver

    19.22
    +0.06 (+0.29%)
     
  • EUR/USD

    1.0206
    +0.0022 (+0.2143%)
     
  • 10-Yr Bond

    2.9130
    +0.1040 (+3.70%)
     
  • Vix

    26.82
    -0.72 (-2.61%)
     
  • GBP/USD

    1.1941
    +0.0019 (+0.1588%)
     
  • USD/JPY

    135.7170
    -0.1980 (-0.1457%)
     
  • BTC-USD

    20,409.36
    +549.62 (+2.77%)
     
  • CMC Crypto 200

    440.06
    +4.54 (+1.04%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,298.66
    +191.01 (+0.73%)
     

Click Therapeutics to Present at the H.C. Wainwright 1st Annual Mental Health Conference

·1 min read

NEW YORK, June 23, 2022--(BUSINESS WIRE)--Click Therapeutics, Inc. ("Click"), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that Randall Stanicky, Chief Financial Officer, will present at the H.C. Wainwright 1st Annual Mental Health Conference on Monday, June 27, 2022 at 11:00 a.m. ET.

The conference will be held in-person at the Lotte New York Palace Hotel in New York City and virtually. For additional information, please visit the conference website.

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program has recently entered a pivotal, fully remote, randomized, controlled trial on the Verily platform for the treatment of Major Depressive Disorder (MDD) in up to 540 adults. Click is progressing a broad pipeline of Digital Therapeutics™ across a variety of high-burden therapeutic areas, including MDD, Schizophrenia, Migraine, Chronic Pain, Atopic Dermatitis, Acute Coronary Syndrome (ACS), Obesity and more. For more information on Click, visit ClickTherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005075/en/

Contacts

Daniel Busby
VP, Investor Relations & Strategic Finance
dbusby@clicktherapeutics.com